You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 11, 2024

GEMFIBROZIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Gemfibrozil, and what generic alternatives are available?

Gemfibrozil is a drug marketed by Natco, Purepac Pharm, Apotex, Ascent Pharms Inc, Aurobindo Pharma Ltd, Cadila, Cadila Pharms Ltd, Caribe Holdings, Chartwell Molecules, Chartwell Rx, Hikma Pharms, Impax Pharms, Invagen Pharms, Northstar Hlthcare, Norvium Bioscience, Sun Pharm Inds Inc, Teva, and Watson Labs. and is included in twenty NDAs.

The generic ingredient in GEMFIBROZIL is gemfibrozil. Thirty-four suppliers are listed for this compound. Additional details are available on the gemfibrozil profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Gemfibrozil

A generic version of GEMFIBROZIL was approved as gemfibrozil by CHARTWELL MOLECULES on September 27th, 1993.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GEMFIBROZIL?
  • What are the global sales for GEMFIBROZIL?
  • What is Average Wholesale Price for GEMFIBROZIL?
Drug patent expirations by year for GEMFIBROZIL
Drug Prices for GEMFIBROZIL

See drug prices for GEMFIBROZIL

Drug Sales Revenue Trends for GEMFIBROZIL

See drug sales revenues for GEMFIBROZIL

Recent Clinical Trials for GEMFIBROZIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St. Louis UniversityEarly Phase 1
Polaryx Therapeutics, Inc.Phase 3
Bristol-Myers SquibbPhase 1

See all GEMFIBROZIL clinical trials

Medical Subject Heading (MeSH) Categories for GEMFIBROZIL
Anatomical Therapeutic Chemical (ATC) Classes for GEMFIBROZIL

US Patents and Regulatory Information for GEMFIBROZIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Natco GEMFIBROZIL gemfibrozil CAPSULE;ORAL 073466-001 Jan 25, 1993 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva GEMFIBROZIL gemfibrozil TABLET;ORAL 074256-001 Oct 31, 1993 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cadila Pharms Ltd GEMFIBROZIL gemfibrozil TABLET;ORAL 203266-001 Jun 17, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ascent Pharms Inc GEMFIBROZIL gemfibrozil TABLET;ORAL 214603-001 Jan 13, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Impax Pharms GEMFIBROZIL gemfibrozil TABLET;ORAL 078207-001 Jun 1, 2007 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs GEMFIBROZIL gemfibrozil TABLET;ORAL 074442-001 Apr 28, 1995 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Caribe Holdings GEMFIBROZIL gemfibrozil TABLET;ORAL 078012-001 Mar 26, 2007 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.